Sage Reports Positive Top-line Results Including Demonstration of 30-Day Durability from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression (Sage Therapeutics Inc)

(Source: Sage Therapeutics Inc) Primary endpoint achieved with statistical significance at 60 hours maintained through 30 days 70% remission achieved at 60 hours of SAGE-547 treatment and maintained at 30-day follow-up Company expects to pursue further development of SAGE-547 and SAGE-217 for PPD in a global clinical program Conference call scheduled for 8:00 AM ET today CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive top-line results from its Phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum...